FDA approved Epi proColon, a blood-based colorectal cancer screening test developed by Epigenomics AG. Epi proColon will be made available in the U.S. under a joint commercialization agreement with Epigenomics partner Polymedco. Epi proColon is indicated for colorectal cancer screening in average-risk patients who choose not to undergo colorectal cancer screening by guideline-recommended methods such...
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
